Skip to main
CALC
CALC logo

CalciMedica Inc (CALC) Stock Forecast & Price Target

CalciMedica Inc (CALC) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CalciMedica Inc. is advancing its lead product candidate, Auxora, which has demonstrated a significant clinical benefit in reducing mortality rates in patients with acute kidney injury (AKI) associated with severe COVID-19 pneumonia, reporting a 62.7% relative reduction in mortality at day 30. The ongoing KOURAGE Phase 2 trial, focused on evaluating Auxora's effectiveness for AKI with acute hypoxemic respiratory failure, stands to further bolster the company's prospects for adoption given the potential benefits, including decreased need for dialysis and improved renal recovery. The promising outcomes observed in the CARDEA trial, particularly for the AKI subgroup, underline Auxora's potential to establish itself as a critical therapeutic option in treating serious inflammatory and immunologic diseases.

Bears say

CalciMedica's financial outlook appears negative due to the potential for failed or inconclusive clinical trials, which can significantly hinder the development of its product candidates. The company also faces challenges in securing adequate funding to progress its drug, Auxora, through necessary stages of development, raising concerns about its financial viability. Additionally, the recent announcement of a first-quarter 2025 earnings per share (EPS) of ($0.36), which fell short of both estimates and consensus expectations, underscores ongoing operational difficulties that could further impact investor confidence.

CalciMedica Inc (CALC) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CalciMedica Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CalciMedica Inc (CALC) Forecast

Analysts have given CalciMedica Inc (CALC) a Strong Buy based on their latest research and market trends.

According to 2 analysts, CalciMedica Inc (CALC) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CalciMedica Inc (CALC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.